BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30509087)

  • 1. Detection of driver mutations in FFPE samples from patients with verified malignant melanoma.
    Malicherova B; Burjanivova T; Minarikova E; Kasubova I; Pecova T; Bobrovska M; Homola I; Lasabova Z; Plank L
    Neoplasma; 2019 Jan; 66(1):33-38. PubMed ID: 30509087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational status of naevus-associated melanomas.
    Shitara D; Tell-Martí G; Badenas C; Enokihara MM; Alós L; Larque AB; Michalany N; Puig-Butille JA; Carrera C; Malvehy J; Puig S; Bagatin E
    Br J Dermatol; 2015 Sep; 173(3):671-80. PubMed ID: 25857817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.
    Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C
    Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
    Lade-Keller J; Rømer KM; Guldberg P; Riber-Hansen R; Hansen LL; Steiniche T; Hager H; Kristensen LS
    J Mol Diagn; 2013 Jan; 15(1):70-80. PubMed ID: 23159593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
    Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
    J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.
    Anderson S; Bloom KJ; Vallera DU; Rueschoff J; Meldrum C; Schilling R; Kovach B; Lee JR; Ochoa P; Langland R; Halait H; Lawrence HJ; Dugan MC
    Arch Pathol Lab Med; 2012 Nov; 136(11):1385-91. PubMed ID: 22332713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas.
    Potrony M; Badenas C; Naerhuyzen B; Aguilera P; Puig-Butille JA; Tell-Marti G; Díaz A; Carrera C; Alos L; Delahaye N; Malvehy J; Puig S
    Clin Chem Lab Med; 2016 Nov; 54(11):1733-1738. PubMed ID: 27101548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR.
    How-Kit A; Lebbé C; Bousard A; Daunay A; Mazaleyrat N; Daviaud C; Mourah S; Tost J
    Anal Bioanal Chem; 2014 Sep; 406(22):5513-20. PubMed ID: 24969466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens.
    Cheng LY; Haydu LE; Song P; Nie J; Tetzlaff MT; Kwong LN; Gershenwald JE; Davies MA; Zhang DY
    Sci Rep; 2021 Apr; 11(1):9043. PubMed ID: 33907234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma.
    Richter A; Grieu F; Carrello A; Amanuel B; Namdarian K; Rynska A; Lucas A; Michael V; Bell A; Fox SB; Hewitt CA; Do H; McArthur GA; Wong SQ; Dobrovic A; Iacopetta B
    Sci Rep; 2013; 3():1659. PubMed ID: 23584600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
    Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
    Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.
    De Paoli-Iseppi R; Johansson PA; Menzies AM; Dias KR; Pupo GM; Kakavand H; Wilmott JS; Mann GJ; Hayward NK; Dinger ME; Long GV; Scolyer RA
    Pathology; 2016 Apr; 48(3):261-6. PubMed ID: 27020503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
    Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
    [No Abstract]   [Full Text] [Related]  

  • 16. A HRM assay for identification of low level BRAF V600E and V600K mutations using the CADMA principle in FFPE specimens.
    Huebner C; Weber R; Lloydd R
    Pathology; 2017 Dec; 49(7):776-783. PubMed ID: 29100713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A landscape of driver mutations in melanoma.
    Hodis E; Watson IR; Kryukov GV; Arold ST; Imielinski M; Theurillat JP; Nickerson E; Auclair D; Li L; Place C; Dicara D; Ramos AH; Lawrence MS; Cibulskis K; Sivachenko A; Voet D; Saksena G; Stransky N; Onofrio RC; Winckler W; Ardlie K; Wagle N; Wargo J; Chong K; Morton DL; Stemke-Hale K; Chen G; Noble M; Meyerson M; Ladbury JE; Davies MA; Gershenwald JE; Wagner SN; Hoon DS; Schadendorf D; Lander ES; Gabriel SB; Getz G; Garraway LA; Chin L
    Cell; 2012 Jul; 150(2):251-63. PubMed ID: 22817889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of an NGS mutation detection panel for melanoma.
    Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
    BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
    Janku F; Claes B; Huang HJ; Falchook GS; Devogelaere B; Kockx M; Bempt IV; Reijans M; Naing A; Fu S; Piha-Paul SA; Hong DS; Holley VR; Tsimberidou AM; Stepanek VM; Patel SP; Kopetz ES; Subbiah V; Wheler JJ; Zinner RG; Karp DD; Luthra R; Roy-Chowdhuri S; Sablon E; Meric-Bernstam F; Maertens G; Kurzrock R
    Oncotarget; 2015 Sep; 6(29):26886-94. PubMed ID: 26330075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
    Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.